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Objective: To report an unusual case of significant neurologi-
cal recovery in a 26-year-old growth hormone-deficient fe-
male patient with significant neurological sequelae resulting 
from brain surgery at 11 years of age.
Design: Case report.
Results: Most of the neurological sequelae present at admis-
sion recovered after 8 months of combined growth hormone 
administration and kinesitherapy/speech therapy. these 
include an increase in tongue size and mobility and in the 
amount and quality of saliva, improvement in vocal cords 
function, recovery of oesophageal peristalsis and disappear-
ance of sleep apnoea.
Conclusion: since the patient had undergone intensive phys-
ical rehabilitation for a 15-year period with no significant 
improvement, it is tempting to speculate that the correction 
of growth hormone deficiency improved her rehabilitation. 
Therefore, we propose that growth hormone treatment, 
combined with the adequate kinesitherapy, may be a useful 
therapy for effective recovery from some neurological defi-
cits in patients with growth hormone deficiency.
Key words: cranial nerve injuries, vocal cord paralysis, growth 
hormone. 
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INTRODUCTION
Affectation of oropharyngeal structures are fairly common 
sequelae of oncological surgery of the head and the neck. This 
affectation frequently presents as disabling symptoms related 
to dysphagia, aspiration and dysphonia. The oropharyngeal 
defects cannot be neurologically restored (1, 2). 
CASE REPORT
A 26-year-old woman presented with significant neurological 
sequelae (including paralysis of oropharyngeal structures, 
paralysis of vocal cords and lack of primary oesophageal peri-
stalsis) secondary to iatrogenic palsy of cranial nerve pairs IX, 
X and XII resulting from brain surgery (bulbar astrocytoma) at 
age 11 years. Her growth velocity had also slowed down soon 
after surgery and lineal growth had stopped one year later. At 
that time, the patient was diagnosed with growth hormone (GH) 
deficiency, but GH therapy was discouraged due to the risk of 
tumour recurrence. The final height of the patient (1.51 m) was 
approximately 15 cm less than her predicted height. 
At admission, the patient was unable to speak or swallow 
and was at high risk of aspiration. A tracheostomy cuff was 
maintained inflated 24 hours a day, and she required frequent 
clearance of secretions. Feeding was provided through a gastric 
tube. Sleep apnoea was also present and required a positive 
airway pressure system. Exploration showed the existence of 
an atrophic and hypotonic tongue and non-functioning oropha-
ryngeal structures and vocal cords (despite intensive speech 
therapy and oropharyngeal electrotherapy/ kinesitherapy for 15 
years). The presence of GH deficiency (GHD) was confirmed 
on the basis of the reduced GH peak response (< 9 ng/ml) to 
the growth hormone releasing hormone plus arginine test. The 
existence of cognitive affectation was ruled out as the patient 
had high academic scores (she had gained a first degree in 
biology after GH therapy was started). A positron emission 
tomo graphy (PET) scan of the brain showed no residual tu-
moural activity. There were no other symptoms of note. The 
patient was scheduled for oropharyngeal kinesitherapy and 
speech therapy (45 min/day, 5 days/week, for each therapy) 
and, concurrently, GH treatment was started. GH doses (0.01 
mg/kg) were administered subcutaneously at 10.00 h daily, 
prior to rehabilitation therapy. One month later, the GH dose 
was increased to 0.02 mg/kg.
The time-line of the clinical evolution of the patient is 
shown in Table I. An obvious change in the type and amount 
of saliva produced was observed as soon as 15 days after the 
start of treatment, with the highly dense mucous saliva chang-
ing into a more fluid secretion (Fig. 1A and B) indicating a 
recovery of parasympathetic functionality. One month after the 
start of treatment, surface electromyography (EMG) patterns 
improved, indicating an enhancement in neuromuscular con-
duction to the suprahyoid group, tongue and pharynx (Fig. 2). 
Tongue size and mobility also increased significantly at this 
time (Fig. 1A and 1B). Furthermore, the patient’s speech 
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improved progressively, and her vocal cords were fully func-
tional 2 months after the start of treatment (Fig. 1C and 1D). 
Primary oesophageal peristalsis also recovered by this time. 
After 4 months of treatment, functional outcome assessment 
of swallowing (FOAMS) scale (3) score had improved from 
grade 1 on admission to grade 3–4, although the patient’s up-
per esophageal sphincter function did not completely recover, 
avoiding resumption of complete oral feeding (Fig. 1E). Sleep 
apnoea also disappeared 2.5 months after the start of treatment. 
Interestingly, the patient entered into an rapid eye movement 
(REM) phase as soon as she fell asleep, and this phase lasted for 
approximately 76% of the sleep cycle (data not shown). Four 
months after starting the treatment, the tracheal cannula was 
withdrawn, the tracheo stomy incision was surgically closed, 
and nocturnal volumetric ventilation was discontinued. No 
aspirations or adverse clinical events were recorded secondary 
to this procedure. The overall condition of the patient improved 
significantly after treatment. However, it is difficult to know 
whether these findings depend directly on GH actions, since 
some improvements secondary to the treatment, such as the 
withdrawal of volumetric ventilation or the absence of sleep 
apnoea, may explain the existence of a better condition and 
alertness.
DISCUSSION
We observed a dramatic improvement in several neurological 
functions in an adult patient with GHD following combined 
kinesitherapy/speech therapy and GH administration. Until 
now the relative impact of the aforementioned treatments on 
the clinical course of the disease had not been clear. However, 
the patient had been undergoing intense rehabilitation for a 15-
year period with no significant improvement, while she began 
to recover shortly after starting GH treatment. Therefore, it is 
reasonable to assume that GH treatment is responsible for the 
clinical benefits reported here. Whilst GH roles in the nervous 
system are starting to emerge, it is presently clear that, apart 
from regulating somatic growth and metabolic processes, GH 
is involved in the regulation of brain growth and development. 
Thus, it has been shown that GH treatment stimulates both 
proliferation and differentiation of neural progenitor cells (4), 
and may promote axonal growth in developing nervous tissues 
(5). A role of GH in the regeneration of the adult central nerv-
ous system (CNS) has been also proposed, since GH treatment 
induces cell proliferation in the brain of adult hypophysect-
omized rats (6). This effect is probably due to the ability of 
GH to stimulate the proliferation and differentiation of adult 
neural stem cell pools present within the CNS (7). All these GH 
actions can be exerted in a direct fashion, through stimulation 
of the GH receptor, which is widely expressed through the 
CNS (8, 9). However, GH may also promote neuronal recovery 
via stimulation of Insulin-like growth factor-1 (IGF1), since 
IGF1 can be produced locally in the brain, and its expression is 
driven by GH (10). In this regard, it is also interesting to note 
that IGF1 gene transfer has been shown to stimulate laryngeal 
reinnervation in rats (11). Finally, GH may also stimulate the 
release of other neurotrophic factors that may have a positive 
impact of neurological recovery (12, 13). In summary, we 
report here for the first time, that correction of GH deficiency 
Fig. 1. (A, B) Changes in tongue size and mobility; (C, D) images from 
videolaryngoscopies showing vocal cords functionality; and (E) barium 
transit across the upper esophageal sphincter (arrows). Upper arrow 
shows the persistence of  barium in the vallecula. Images were obtained 
before the start of treatment (A, C), and after 1 (B), 2 (D), or 4 (E) months 
of treatment. Also notice the difference in the amount of saliva present in 
the mouth (arrows) between (A) and (B). 
Fig. 2. Neuromuscular conduction to the suprahyoid group, tongue and 
pharynx muscles. Surface electromyographic (EMG) activity was measured 
immediately before the beginning of the treatment and then every week 
for 3 months. Two pairs of bipolar skin electrodes (Ag-AgCl) were 
connected to an EMG device and the EMG signal was registered during 
the maximal muscle contraction sustained for 3 sec. The movements 
requested were: antepulsion of the tongue, thrust of the tongue on the 
palate, and swallowing. Results are shown as the percentage increase 
compared with basal, after 1 (grey), 2 (black) or 3 (white) months. Ant: 
antepulsion; Thr: thrust; Swa: swallowing. 
Table I. Time-line of the clinical outcome of the patient
Time 
(months) Clinical outcome 
0.5 Reduced accumulation of saliva in the mouth
Predominance of serous saliva
1 Increased tongue size and motility
Increased oropharyngeal electromyography conduction
2 Recovery of vocal cord function (videolaryngoscope)
Recovery of primary oesophageal peristalsis (oesophagoscopy)
2.5 Absence of episodes of sleep apnoea (polysomnography)
4 Removal of volumetric ventilation
Surgical closure of the tracheostomy
8 Presence of deglution (barium transit)
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improved rehabilitation in a GH-deficient patient. In view of 
these findings, it can be envisaged that treatment combined 
with the adequate kinesitherapy may be a useful therapy for 
effective recovery from neurological deficits in adult patients 
with GHD. In addition, the existence of a GH deficit should 
be also taken into consideration in patients with low response 
to rehabilitation therapy. 
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